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Abstract
Postreplicative mismatch repair (MMR) involves the concerted action of at least 20 polypeptides.
Although the minimal human MMR system has recently been reconstituted in vitro, genetic evidence
from different eukaryotic organisms suggests that some steps of the MMR process may be carried out by
more than one protein. Moreover, MMR proteins are involved also in other pathways of DNA
metabolism, but their exact role in these processes is unknown. In an attempt to gain novel insights into
the function of MMR proteins in human cells, we searched for interacting partners of the MutL
homologues MLH1 and PMS2 by tandem affinity purification and of PMS1 by large scale
immunoprecipitation. In addition to proteins known to interact with the MutL homologues during
MMR, mass spectrometric analyses identified a number of other polypeptides, some of which bound to
the above proteins with very high affinity. Whereas some of these interactors may represent novel
members of the mismatch repairosome, others appear to implicate the MutL homologues in biological
processes ranging from intracellular transport through cell signaling to cell morphology, recombination,
and ubiquitylation.
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Postreplicative mismatch repair (MMR) involves the con-
certed action of at least 20 polypeptides. Although the minimal
human MMR system has recently been reconstituted in vitro,
genetic evidence from different eukaryotic organisms suggests
that some steps of theMMRprocessmay be carried out bymore
than one protein. Moreover, MMR proteins are involved also in
other pathways ofDNAmetabolism, but their exact role in these
processes is unknown. In an attempt to gain novel insights into
the function of MMR proteins in human cells, we searched for
interacting partners of the MutL homologues MLH1 and PMS2
by tandem affinity purification and of PMS1 by large scale
immunoprecipitation. In addition to proteins known to interact
with the MutL homologues during MMR, mass spectrometric
analyses identified a number of other polypeptides, some of
which bound to the above proteins with very high affinity.
Whereas some of these interactors may represent novel mem-
bers of the mismatch repairosome, others appear to implicate
the MutL homologues in biological processes ranging from
intracellular transport through cell signaling to cell morphol-
ogy, recombination, and ubiquitylation.
The postreplicative mismatch repair (MMR)2 system main-
tains genomic stability by removing replication errors from
DNA and by controlling the fidelity of recombination events,
bothmitotic andmeiotic (1–4). Despite the fact that the human
MMRpathwaywas recently reconstituted in vitro frompurified
individual components (5, 6), our knowledge of the molecular
mechanisms of this process is still incomplete. The repair reac-
tion requires a mismatch recognition step, which is mediated
by the heterodimers of MSH2 (MutS homologue 2) and MSH6
(MutS) or MSH2 and MSH3 (MutS). MutS preferentially
recognizes single basemismatches and small insertion-deletion
loops (7, 8), whereas MutS recognizes preferentially larger
insertion-deletion loops (9). Uponmismatch binding, theMutS
( or ) heterodimer associates with the heterodimeric com-
plex of MLH1 (MutL homologue 1) and PMS2 (postmeiotic
segregation 2) (MutL) thatwas shown to be essential for repair
(10). Until recently, the biochemical function of the MutL pro-
tein homologues remained enigmatic. MutL was believed to
couple themismatch recognition step to downstreamprocesses
that include the removal of the mismatch from the nascent
DNA strand, resynthesis of the degraded region, and ligation of
the remaining nick (1, 11). MutLwas shown to possess a weak
ATPase activity (12) that is essential for MMR, but the contri-
bution of this enzymatic function to DNA metabolism was
unclear. Most recently however, MutL was shown to possess
also an endonuclease activity, which introduces additional
nicks into the discontinuous strand and thus facilitates the 5 to
3 degradation of the mismatch-containing strand by EXO1
(13, 14). This latter function helped explain why both EXO1, a
5 to 3 exonuclease, andMutL, are required for 3 to 5MMR.
Moreover, characterization of the endonuclease activity of
MutL requires that the involvement of this heterodimer in
biological processes other than MMR must be reexamined.
MLH1 can bind two other humanMutL homologues, PMS1
and MLH3, to form the heterodimers MutL and MutL,
respectively. In vitro studies failed to identify a role ofMutL in
MMR (15), whereasMutL canparticipate in the repair of base-
base mismatches and small insertion-deletion loops, although
its in vivo role seems to be only marginal (16). Interestingly, the
active site of theMutL endonuclease resides in the PMS2 sub-
unit and is conserved in MLH3 but not in PMS1 (14). This
explains why MutL and MutL are active in MMR, whereas
MutL is not.
MMRdefects in humans are linked to hereditary nonpolypo-
sis colon cancer, with MLH1 mutations being responsible for
60% of the cases. Animal models of the disease confirm this
link; disruption ofMsh2 andMlh1 is associated with the most
tumor-prone phenotype, whereas the severity of mutations in
animals null forMsh6,Pms2, andMlh3 is reduced,which can be
explained by the redundant roles played by the polypeptides
encoded by the products of these genes in MMR. Correspond-
ingly, mice lacking both MSH3 and MSH6 have a similar phe-
notype to animals deficient inMSH2, and those doubly mutant
in MLH3 and PMS2 resemble MLH1-deficient mice (17–20).
However, the biochemical roles of MMR proteins go beyond
mismatch repair.
Themousemodels confirmed the involvement ofMMRpro-
teins in mitotic recombination (19), since MLH1/ (21) and
MLH3/ (22) knockout mice are not only cancer-prone but
also sterile. Interestingly, in PMS2/ animals, sterility is a fea-
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ture of male mice only (23), suggesting that PMS2 may have a
more limited spectrum of meiotic functions than MLH1 and
MLH3 (1, 24).
The importance of MMR proteins in DNA metabolism is
further underscored by the findings thatMMRstatus affects the
outcome of other key processes, such as single strand annealing
(25), class switch recombination, and somatic hypermutation
of immunoglobulin genes (26), as well as triplet repeat expan-
sions (27). Unfortunately, we currently lack mechanistic
insights into these processes. In an attempt to elucidate the
involvement of the MMR proteins in the above (and perhaps
even in as yet unlinked) biological pathways, we set out to study
the interactome of the human MutL homologues by tandem
affinity purification (TAP). Several reports provide evidence
that this technique, originally established in Saccharomyces cer-
evisiae (28, 29), represents a major improvement in the identi-
fication of protein-protein interactions. TAP represents a val-
uable method to identify interacting proteins in vivo, under
native conditions and with a high degree of selectivity (30). We
also carried out a large scale immunoprecipitation of PMS1 and
analyzed the interacting partners of this thirdMutL homologue
bymass spectrometry (MS).Our efforts led to the identification
of a number of proteins complexed with MLH1, PMS1, or
PMS2, some of which were described previously but themajor-
ity of which represented new interacting partners. It is hoped
that further study of these interactions will help us uncover
novel roles of the enigmatic MutL homologue family in human
cells.
EXPERIMENTAL PROCEDURES
Plasmid Constructions—The mammalian vector for the
expression of N-terminally TAP-tagged MLH1 was created by
inserting the cDNA encoding the full-length MLH1 into the
EcoRI site of pZome-1-N (Cellzome), and the vector for the
expression of C-terminally TAP-tagged PMS2 was created by
inserting the cDNA encoding the full-length PMS2 into the
BamHI site of pZome-1-C (Cellzome). The vectors for the
mammalian expression of Amot (angiomotin)/p80 and Amot/
p130 were kindly provided by Dr. L. Holmgren (Karolinska
Institute, Stockholm, Sweden). The pCDNA3-HA-Ubi vector,
encoding HA-tagged ubiquitin, was kindly provided by Dr. D.
Bohmann (School of Medicine and Dentistry, University of
Rochester, Rochester, NY).
Cell Culture and Transfections—The human 293, 293T, and
HeLa cells were obtained from the cell line repository of Cancer
Network Zurich, and the HeLa12 cell line was kindly provided
by Dr. M. Bignami (ISS, Rome, Italy). All of the cell lines were
cultured at 37 °C in a 5% CO2 humidified atmosphere and
maintained in the appropriate media. Transfection was per-
formed using the Fugene 6 transfection reagent (RocheApplied
Science) according to the manufacturer’s recommendations.
For generation of stable cell lines, 0.2 g/ml puromycin (Invi-
vogen) was added to the medium 1 day after transfection. After
2 weeks, the surviving colonies were isolated and their extracts
were screened byWestern blot using antibodies against MLH1
and PMS2. The clones showing the highest expression of the
two tagged mismatch repair proteins were further subcloned.
Western Blot Analyses andAntibodies—Preparation ofwhole
cell extracts and Western blot analyses were performed as
described previously (31) using the following antibodies:MLH1
and PMS2 from BD PharMingen (1:4000 and 1:1000, respec-
tively), -tubulin and BRCA1 (breast cancer-associated pro-
tein-1) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA)
(1:2000 and 1:500, respectively), BRIP1 (BRCA1 interacting
protein C-terminal helicase 1) fromNovus Biologicals (1:4000),
MSH6 fromTransduction Laboratories (1:1000), and ubiquitin
from BAbCO (1:1000). The anti-angiomotin antibody was a
kind gift of Dr. L. Holmgren (Karolinska Institute, Stockholm,
Sweden). For the immunoprecipitation experiment, the anti-
PMS1 rabbit polyclonal antibody (15) was further affinity-puri-
fied. Briefly, 10 mg of purified His6-tagged internal peptide of
PMS1 (amino acids 335–643) were coupled to 0.4 g of CNBr-
activated Sepharose 4B (Amersham Biosciences), according to
the manufacturer’s instructions. 5 ml of rabbit polyclonal anti-
PMS1 serum diluted 10 in 50 mM Tris-HCl, pH 7.5, was then
bound to the CNBr-bound antigen for 4 h at 4 °C. After two
washes in 10 mM Tris-HCl, pH 7.5, and two additional washes
in 10 mM Tris-HCl, pH 7.5, 500 mM NaCl, the antibody was
eluted with 100 mM glycine-HCl, pH 2.5, at 4 °C. The elution
step was repeated twice, and the final eluates were pooled in
new tubes containing 1 M Tris-HCl, pH 8.0, to a final concen-
tration of 100 mM. 300 l of the corresponding preimmune
serumwere IgG/A-purified by binding to 300l of Protein A/G
Plus-agarose (Santa Cruz Biotechnology). Elution of the IgG/A
bound antibodies was then performed as above.
Co-immunoprecipitations—Co-immunoprecipitations were
performed as described previously (16). Control experiments
were done in the absence of the primary antibody. The detec-
tion of PMS1 polyubiquitylation was carried out as described
(32).
Testing ofMMR Status—In vitroMMRassays, theN-methyl-
N-nitro-N-nitrosoguanidine (MNNG) sensitivity assay, and
fluorescence-activated cell sorting analyses were performed as
described previously (31).
TAP—293T and HeLa12 cells stably transfected with plas-
mids expressing the N-terminally TAP-tagged MLH1 and the
C-terminally TAP-tagged PMS2 (TAP-MLH1/293T and TAP-
PMS2/HeLa12 cell lines, respectively) were plated in 15-cm
dishes. Cells were cultured to 80% confluence, washed twice in
cold PBS, and lysed for 30min on ice in 50mMTris-HCl, pH8.0,
125 mM NaCl, 1% Nonidet P-40, 2 mM EDTA, 1 mM phenyl-
methylsulfonyl fluoride, 1 complete inhibitory mixture
(Roche Applied Sciences), 0.5 mM sodium orthovanadate, 20
mM sodium fluoride, and 5 nM okadaic acid. The lysates were
cleared by centrifugation at 12,000 g for 3 min, and the solu-
ble material was collected. Protein concentrations were deter-
mined using the Bradford assay (Bio-Rad).
Tandem affinity purification was performed batchwise
according to the original protocol (29) with minor changes. All
of the following purification steps were performed on ice or at
4 °C. For each experiment, 60 mg of whole cell extract were
incubated for 4 h with gentle agitation with 100 l of IgG-
Sepharose beads (Amersham Biosciences) equilibrated with
lysis buffer. Beads were then washed three times with 1 ml of
lysis buffer and three times with 1 ml of tobacco etch virus
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(TEV) buffer (10 mM Hepes-KOH, pH 8.0, 150 mM NaCl, 0.1%
Nonidet P-40, 0.5 mM EDTA, 1 mM dithiothreitol, 1 mM phen-
ylmethylsulfonyl fluoride, and 1 complete inhibitory mix-
ture). Bound TAP-tagged proteins were released by overnight
incubation in TEV buffer containing 16 units of acTEV prote-
ase (Invitrogen) in tubes mounted on a rotating platform. The
supernatant from the TEV reaction was collected and trans-
ferred to a new tube. One volume of calmodulin binding buffer
(10 mM -mercaptoethanol, 10 mM Hepes-KOH, pH 8.0, 150
mMNaCl, 1mMMgOAc, 1mM imidazole, 0.1%Nonidet P-40, 2
mM CaCl2, 1 mM phenylmethylsulfonyl fluoride, and 1 com-
plete inhibitory mixture) was added to the collected superna-
tant and centrifuged at 1500 rpm for 3 min in an Eppendorf
centrifuge. The supernatant was then transferred to a new tube,
and the procedure described above was repeated two more
times. 1⁄250 volume of 1 M CaCl2 was then added, and the super-
natant was batch-purified by binding to 100 l of calmodulin
affinity resin (Stratagene) equilibrated in calmodulin binding
buffer for 4 h on a rotating platform. Beads were washed three
times with 1.2 ml of calmodulin binding buffer and twice with
1.2 ml of calmodulin rinsing buffer (50 mM ammonium bicar-
bonate, pH 8.0, 75 mM NaCl, 1 mM MgOAc, 1 mM imidazole,
and 2 mM CaCl2) and eluted with 100 l of calmodulin elution
buffer (50 mM ammonium bicarbonate, pH 8.0, and 35 mM
EGTA). One-third of the eluate was separated by SDS-PAGE
and visualized by silver staining. As negative control, the puri-
fication was performed with extracts prepared from parental
cells not expressing the tagged protein.
Liquid Chromatography-MS/MS Analysis—The eluate from
two TAP experiments (total volume 200 l) was concentrated
using the Microcon YM-3 concentrator (Millipore) according
to the manufacturer’s instructions, separated by 7.5% SDS-
PAGE and visualized by Coomassie staining. The gel was then
cut into 11 slices, and the polypeptides were subjected to in-gel
tryptic digest. Briefly, the gel slices were cut into small frag-
ments and subjected to two cycles of rehydration in 50 mM
ammonium bicarbonate and shrinking by dehydration in 80%
acetonitrile. The proteins were then reduced with 37mM dithi-
othreitol in 50 mM ammonium bicarbonate at 50 °C for 30 min.
After two rounds of dehydration, the proteins were alkylated
with 20 mM iodoacetamide in 50 mM ammonium bicarbonate
for 15min at room temperature in the dark. After three further
rounds of rehydration and shrinking, the gel pieces were incu-
bated with 200 ng of sequencing grade modified trypsin (Pro-
mega) for 4 h at 37 °C and then at 25 °C overnight. The peptides
were extracted by one change of 0.1% formic acid and three
changes of 80% acetonitrile, 0.1% formic acid and dried under
vacuum. The tryptic peptides were analyzed on an LTQ-FTTM
analyzer (Thermo Electron, Bremen, Germany). Peptides were
separated on a nano-high pressure liquid chromatograph (Agi-
lent, Palo Alto, CA) online prior to MS analysis on a C18
reversed phase column (Magic 5-m100-Å C18 AQ;Michrom,
Auburn, CA), using an acetonitrile/water system at a flow rate
of 200 nl/min. Tandem mass spectra were acquired in a data-
dependent manner. Typically, four MS/MS were performed
after each high accuracy spectral acquisition range survey. The
human portion (taxonomy ID: 9606) of the UniProt data base
(available on the Internet at ftp.ebi.ac.uk/pub/databases/SP
proteomes/fasta/proteomes/25.H_sapiensfasta.gz) was inter-
rogated using the Mascot search algorithm (33). One failed
trypsin cleavage was allowed per search. The precursor and
fragment ion tolerances were set to 5 ppm and 0.8 Da,
respectively.
RESULTS
Generation and Characterization of Stable Mammalian Cell
Lines Expressing TAP-tagged MLH1 and PMS2—TAP was
shown to be a powerful method for identification of interacting
partners of known proteins in various host cell lines (29, 30). In
order to avoid competition, it is preferable to use cell lines lack-
ing the corresponding endogenous protein. For this reason, we
stably transfected two human cell lines deficient for MLH1 or
PMS2, namely the MLH1-deficient embryonic kidney cell line
293T (34) and the PMS2-deficient ovarian carcinoma cell line
HeLa12 (35) with pZome-1-N-MLH1 and pZome-1-C-PMS2,
respectively. The resulting clones were analyzed by Western
blot for the expression of the TAP-tagged protein MLH1 or
PMS2 (see “Experimental Procedures” for details). Since the
stable clones exhibited different expression levels of the trans-
fected proteins (data not shown), we selected two that
expressed the TAP-tagged proteins at levels comparable with
those present in the MMR-proficient cell line HeLa (Fig. 1A).
The TAP-tagged proteins translocated in both cases into the
nucleus as ascertained by indirect immunofluorescence or
immunohistochemistry (data not shown).
To rule out the possibility that the TAP tag impairs the func-
tion ofMLH1orPMS2,weperformed in vitroMMRassayswith
cytoplasmic extracts from TAP-MLH1/293T and TAP-PMS2/
HeLa12 cells. As shown in Fig. 1B, theMMRactivity in both cell
lines was comparable with the repair activity of MMR-profi-
cient HeLa cells.
Treatment of mammalian cells with low doses of SN1 type
alkylating agents, such asMNNG, induces a G2 cell cycle arrest
that is absolutely dependent on functional MMR (36). We con-
firmed this hallmark of MMR proficient cells in our stable cell
lines by fluorescence-activated cell sorting analysis. Both TAP-
MLH1/293T and TAP-PMS2/HeLa 12 cell lines arrested in the
G2 phase of the cell cycle upon treatment with 0.2 M MNNG
for 24 h (Fig. 1C). The arrest of cell growth upon treatmentwith
MNNG was also confirmed by clonogenic assays (data not
shown). In summary, the TAP tag impairs the function of nei-
ther MLH1 nor PMS2 in MMR.
Tandem Affinity Purifications—Since its first description in
1999 (28), TAP tagging has been successfully used in the
identification of binding partners of various proteins (29,
30). The affinity tag consists of two IgG binding domains of
the Staphylococcus aureus protein A and of a calmodulin
binding peptide, whereby the two motifs are separated by a
TEV protease cleavage site. We placed the TAP tag at the N
terminus of MLH1, since the C terminus of this polypeptide
is extremely sensitive to modification (37), and at the C ter-
minus of PMS2 (Fig. 2A). The protein complexes were then
isolated by chromatography on IgG-Sepharose, followed by
elution with TEV protease and loading onto calmodulin-
Sepharose. The final elution was carried out with EGTA (Fig.
2B). TAP and liquid chromatography-MS/MS analysis (Fig.
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2C) were performed as described under “Experimental Pro-
cedures.” Each experiment was repeated several times, and
the results were highly reproducible, as judged by comparing
silver-stained gels from independent experiments (data not
shown).
Identification of Interacting Part-
ners of MLH1 and PMS2—Each
TAP experiment was performed
with 2  60 mg of whole cell
extracts. Upon concentration, the
final eluate was subjected to electro-
phoresis on SDS-PAGE, and the
protein bands were visualized by sil-
ver staining for analytical purposes
and by Coomassie Blue staining for
MS analysis. The bait protein and its
partner(s) were detected as themost
prominent bands, migrating at the
predicted molecular sizes (Fig. 3A).
The identity of these bands was also
independently confirmed by West-
ern blotting (Fig. 3B). The lanes
containing the TAP eluates were
then cut into 11 slices, and the pro-
teins in each slice were identified by
MSanalysis of their tryptic peptides.
As anticipated, the highest Mascot
scores belonged to MLH1, PMS1,
and PMS2, but we were able to
identify also a large number of
other proteins in the TAP-MLH1
or TAP-PMS2 eluates. First, we
verified that the detected proteins
were isolated from the gel area
corresponding to their predicted
molecular sizes. Next, we classified
the proteins into several groups
according to the known function. A
selection of MLH1 and PMS2 inter-
actors are listed in Tables 1 and 2,
respectively.
In the MLH1-TAP experiment,
one of themost prominent polypep-
tides was PMS1 (Fig. 3, A (left) and
C), which interacts in vivo with
MLH1 to form the heterodimer
MutL (15). As noted above, PMS1
lacks the endonuclease active site
conserved in PMS2 andMLH3 (14),
and mice lacking this polypeptide
are not cancer-prone (17). The bio-
logical roles of PMS1 and MutL
thus remain enigmatic. As antici-
pated, we found PMS1 associated
with MLH1 in the TAP eluate from
the cell line expressing TAP-tagged
MLH1, but not TAP-tagged PMS2
(Fig. 3A) (Tables 1 and 2), which
confirms that PMS2 and PMS1 compete for MLH1 (15, 37).
Given that the intracellular level of PMS1 was reported to be
lower than that of PMS2 (15), the fact that these two proteins
were pulled down in similar amounts shows that the affinity of
MLH1 for PMS1 is high.
FIGURE 1. Characterization of mammalian cell lines stably expressing TAP-tagged MLH1 and PMS2.
A, whole cell extracts of TAP-MLH1/293T (left) and TAP-PMS2/HeLa12 cells (right) were analyzed by West-
ern blot (50 g of extract/lane) for the expression of MLH1 and PMS2. In both cell lines, the expression of
the TAP-tagged proteins was roughly comparable with the amounts of these proteins in 50 g of whole
cell extract from the MMR-proficient cell line HeLa (left). Note that TAP-MLH1 and TAP-PMS2 migrate
slower due to the presence of the TAP tag. B, in vitro MMR assays. The repair efficiency of the extracts of
TAP-MLH1/293T (left) and TAP-PMS2/HeLa12 (right) cells was compared with the repair efficiency of the
extracts from corresponding parental MMR-deficient cell lines 293T or HeLa12, respectively. The repair
efficiencies were determined on hetroduplex substrates containing a G/T mismatch (for details, see
“Experimental Procedures”). Extracts from the MMR-proficient HeLa cells were used as a positive control.
C, FACS profiles of theMMR-proficient or -deficient 293 and 293T cells (left) andHeLa or HeLa12 cells (right)
were compared with the profiles of TAP-MLH1/293T (left) and TAP-PMS2/HeLa12 (right) cells either
untreated or treated with 0.2 M MNNG for 24 h. The figure shows that expression of the TAP-tagged
variants of MLH1 and PMS2 restored MMR proficiency and cell cycle checkpoint activation to the MMR-
deficient cell lines 293T and HeLa12.
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The interaction ofMLH1 withMLH3, which forms the third
MLH1-containing heterodimer, MutL, could not be con-
firmed, because the MLH3 gene in the 293T cell line is tran-
scriptionally silenced by promoter methylation (16).
Our analysis (Tables 1–3) identified also several other previ-
ously described interactors. The 5–3 exonuclease EXO1,
which was shown to interact with MutL in co-immunopre-
cipitation and pull-down experiments (38, 39), was present in
both MLH1-TAP and PMS2-TAP fractions. Proliferating cell
nuclear antigenwas shown to interact withMLH1 in yeast two-
hybrid and co-immunoprecipitation experiments (40, 41).
Although we did not identify proliferating cell nuclear antigen
peptides in the eluate fromTAP-MLH1with a significant score,
the protein was present at significant levels in the complex
FIGURE 2. Tandemaffinity purifications. A, schematic representation of theMLH1-TAP (top) and PMS2-TAP (bottom) constructs. The TAP tagwas inserted at
the N terminus of MLH1 and at the C terminus of PMS2. Prot A, Protein A (IgG binding) domain; TEV, TEV protease cleavage site; CBD, calmodulin binding
domain. B, overview of the purification procedure. Black circles, factors that specifically interact with the bait protein;white circles, noninteractors (see“Results”
for details). C, tandemmass spectra of tryptic peptides from PMS2 and MLH1 identified in the TAP of MLH1 and PMS2, respectively. For clarity, only the y-ion
series are labeled in both panels. The top shows the MS/MS spectrum of [M 2H]2  901.4644, which was identified as the peptide ELVENSLDAFATNIDLK
fromPMS2 found in theTAPofMLH1. Thepeptidewas identifiedwithaMascot scoreof 104,whereas theoverall protein coveragewas59%witha scoreof 4117.
The bottom shows the MS/MS spectrum of [M 2H]2  733.9164. The peptide identified was KAIETVYAALPK from MLH1 found in the TAP of PMS2, with a
peptide ion score of 97. The overall protein coverage was 85% with a Mascot score of 4158.
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bound to PMS2. In addition to EXO1 and proliferating cell
nuclear antigen, we could detect other proteins involved in
MMR, including MSH2, MSH6, and replication factor C,
among the PMS2-bound proteins. Thus, with the notable
exception of DNA polymerase  and replication protein A, fac-
tors required for the recently reconstituted MMR reaction in
vitro (5) were specifically detected in the TAP eluates.
MLH1 was also described to associate with the breast cancer
susceptibility gene product BRCA1 in the so-called BASC com-
plex (42). The same group later described the binding of BRCA1
to SMC1 (structuralmaintenance of
chromosome protein 1) upon DNA
damage (43). The finding of both
proteins, BRCA1 and SMC1, in our
TAP-MLH1 eluate is a further
validation of our experimental
conditions.
Although many interactions be-
tween our bait proteins and their
known interacting factors could be
confirmedwithourTAPstrategy, this
was not always the case. For instance,
we failed to detect interactions
betweenMLH1 and the Bloom’s heli-
case (44), MRE11 (45), or MBD4
(methyl-CpG binding domain pro-
tein 4) (MED1) (46). This could be
explained by the differences be-
tween the TAP protocol and the
experimental systems deployed in
the latter studies. Moreover, we can-
not exclude the possibility that the
presence of the TAP tag on our bait
proteins interfered with the binding
of these polypeptides.
The primary focus of this study
was to detect novel interacting part-
ners of the human MutL homo-
logues, in an attempt to explain the
involvement of these proteins in
MMR and other biological pro-
cesses. As shown in Tables 1 and 2,
the TAP approach succeeded in
identifying numerous novel part-
ners of both MLH1 and PMS2. For
example, MLH1 appears to be in a
stable complexwithAmot (Table 1).
This polypeptidewas identified dur-
ing a search for angiostatin interac-
tors in a yeast two-hybrid assay (47).
We were initially skeptical about this
assignment for two reasons. First, the
80-kDa Amot was reported to be
involved in thecontrolofmigrationof
endothelial cells, and second, ourMS
analysis identified Amot in an SDS-
PAGE band that was expected to
contain proteins in the 120–130-
kDa range. Interestingly, a few weeks after we identified Amot
as an MLH1-interacting protein, an alternatively spliced iso-
form of Amot, which has a molecular size of 130 kDa, was
described (48, 49). It appears to localize to cell-cell junctions
and affect endothelial cell shape (48). We confirmed the
specificity of the interaction betweenMLH1 and angiomotin
p130 by co-immunoprecipitation (Fig. 3D).
It is known that both MLH1 and PMS2 contain a monopar-
tite nuclear localization signal and that certain mutations
within this nuclear localization signal impair their nuclear
FIGURE 3.Analysis ofMLH1- andPMS2-interactingpartners by TAP.A, analysis of the TAP-MLH1 (left panel,
right lane) and TAP-PMS2 (right panel, right lane) interactomes. TAPwith extracts from corresponding parental
untransfected cells (middle lanes) were used as negative controls. One-third of the final eluate from 60 mg of
whole cell extract (see “Experimental Procedures” for details) was resolved on SDS-PAGE and visualized by
silver staining. The bands corresponding to the tagged protein and itsmajor in vivo interactor(s) are indicated.
M, molecular size marker; CBD, calmodulin binding domain. B, Western blot analyses. 50 g of whole cell
extract (WCE) or 33 l of TAP eluate were loaded on SDS-PAGE and analyzed by Western blot using specific
antibodies against human MLH1 and PMS2. Extracts and eluates from parental untransfected cell lines 293T
(left panel) and HeLa12 (right panel) were compared with samples from the stable cell lines TAP-MLH1/293T
(left) and TAP-PMS2/HeLa12 (right). Note that the TAP-tagged MLH1 and PMS2 migrate slower due to the
presence of the TAP tag or of the CBD. C, relative abundance of PMS1 and PMS2 in TAP eluates. 50g of whole
cell extract from293T and TAP-MLH1/293T cells or 33l of the final eluate from the TAP-MLH1were loaded on
SDS-PAGE and analyzed byWestern blot using specific antibodies against human PMS1 and PMS2.D, 293 cells
were transiently transfected with the cDNA encoding Amot/p130. One mg of whole cell extract from the
transfected cells was incubated with (IP MLH1) or without (CTRL) the anti-MLH1 antibody. E, co-immunopre-
cipitation of MLH1 and BRIP1 in HeLa cells. 500 g of whole cell extract were incubated with or without
anti-MLH1 antibody (top) or anti-BRIP1 antibody (bottom). DNase, extract treated with DNase prior to IP. This
experiment shows that the interaction between BRIP1 and MLH1 is not mediated by DNA. This reaction was
carried out in the presence of 25 units of benzonase.
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import (50, 51). Nuclear localization signals are recognized by
specialized transport factors, karyopherins or importins, which
function as heterodimeric protein complexes that dock to
nuclear localization signal-containing substrates and mediate
their import into the nucleus (52). We identified importin 2
and its known binding partner importin1 in the complexwith
both MLH1 and PMS2 (Tables 1 and 2). This finding suggests
that the importin 2/1 heterodimer might be the nuclear
transporter of human MutL.
Of particular interest is the identification of BRCA1-associ-
ated C-terminal helicase BRIP1 (also known as BACH1), in the
MLH1- and PMS2-bound complexes (Tables 1 and 2). BRIP1/
BACH1was recently identified as the Fanconi anemia J protein
(53–55) and appears to be critical for homologous recombina-
tion, DNA double strand break repair, and interstrand cross-
link repair (55, 56). We confirmed the binding of BRIP1 to
MLH1 by reciprocal immunoprecipitation and Western blot
(Fig. 3E). BRCA1 was also present in the complex.
As mentioned above, the interaction between BRCA1 and
MLH1 had been described earlier (42) and could be confirmed
in the present study. However, the low protein score for BRCA1
(Table 1) suggested either that the interactionwas onlyweak or,
alternatively, that BRCA1 was bound to MLH1 indirectly, pos-
sibly via BRIP1. The same could apply also to BRG1/
SMARCA4/SMCA4 (Table 2). This polypeptide has been
reported to interact with BRCA1 and is believed to act as a
cofactor of c-Myc in oncogenic transformation (57). It has a
DNA-dependent ATPase activity, which may be required for
TABLE 1
The TAP interactome of MLH1
The table lists a selection of proteins identified in theMLH1-TAP eluate. The full list






MLH1 7390 70 P40692
PMS1 7143 70 P54277
PMS2 4117 59 P54278
MSH3 628 22 P20585
Exonuclease 1 72 6 Q5T396
DNAmetabolism/repair
DNA-PKcs 483 9 P78527
BRCA1 202 11 Q5YLB2
SMC1A 68 10 Q14683
SEP1 (XRN1) 330 9 Q8IZH2
Protein import/export
Importin 2 336 18 P52292
Importin 1 118 3 Q14974
Ubiquitin pathway/proteasome
PSD3 243 18 O43242
UBP2L 183 12 Q14157
Ubiquitin 172 45 P62988
DNA helicases
BRIP1 (BACH1) 3905 53 Q9BX63
RuvB-like 1 309 22 Q9Y265
RuvB-like 2 76 8 Q9Y230
Unknown function/hypothetical
proteins
KIAA1018 (fragment) 898 27 Q9Y2M0
YLPM1 (ZAP3) 184 3 P49750
Cell cycle/signaling/kinases/
phospatases/apoptosis
PP2A regulatory subunit A- 278 19 P30153
PP2A regulatory subunit B- 152 10 P63151
PP2A regulatory subunit B- 99 6 Q00005
P2BB catalytic subunit  184 19 P16298
P2BC catalytic subunit  122 10 P48454
PP2A regulatory subunit B- 99 8 Q6IN90
PDCD8 169 15 O95831
PI3K-C2 160 6 O00443
Others
Angiomotin 4013 57 Q4VCS5
ATAD3A 470 25 Q9NVI7
DOCK7 460 9 Q5T1C0
PYGB 269 10 P11216
ATP 953 39 P25705
ATAD3B 244 19 Q5T9A4
REC14 (WDR61) 155 7 Q6IA22
aDerived from the Swiss-Prot data base or published data.
bMascot protein score of65 was considered significant (p 0.05).
TABLE 2
The TAP interactome of PMS2
The table lists a selection of proteins identified in the PMS2-TAP eluate. The full list








MLH1 4158 85 P40692
PMS2 3601 71 P54278
MSH2 1529 31 P43246
MSH3 993 24 P20585
MSH6 108 4 P52701
Exonuclease 1 164 12 Q5T396
PCNA 184 15 P12004
RFC 40 kDa 82 10 P35250
DNAmetabolism/repair
DNA-PKcs 1938 13 P78527
BRCA2 114 8 P51587
DDB1 114 8 Q16531
MMS19-like 97 5 Q5T455
CAD (PYR1) 1718 19 P27708
MCM3 130 7 P25205
BRG1 (SMCA4, SMARCA4) 280 5 P51532
Protein import/export
Importin 2 535 22 P52292
Importin 1 425 12 Q14974
CRM1 (XPO1) 797 17 O14980
COPB 741 24 P53618
COPG 170 4 Q9Y678
COPG2 112 7 Q9UBF2
Ubiquitin pathway/proteasome
PSD2 818 24 Q13200
PRS4 378 29 P62191
PRS10 253 14 P62333
PSD5 245 16 Q16401
PSD3 234 14 O43242
PRS6A 132 12 P17980
PRS7 108 7 P35998
Ubiquitin 127 45 P62988
CYLD 241 10 Q9NQC7
EDD 206 8 O95071
DNA helicases
BRIP1 (BACH1) 720 14 Q9BX63
RuvB-like 1 710 33 Q9Y265
RuvB-like 2 570 24 Q9Y230
Unknown function/hypothetical
proteins
KIAA1018 (fragment) 454 14 Q9Y2M0
DKFZp686L22104 103 21 Q68E03
Cell cycle/signaling/kinases/
phospatases/apoptosis
PP2A catalytic subunit  131 12 P67775
PDCD8 90 6 O95831
PI3K-C2 67 9 O00443
Others
ATAD3A 571 30 Q9NVI7
NSUN2 145 10 Q9BVN4
a Derived from the Swiss-Prot data base or published data.
bMascot protein score of65 was considered significant (p 0.05).
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transcriptional activation of certain genes (58) as part of a SWI/
SNF chromatin remodeling complex (59). This latter complex
contains also twoproteins related to the bacterial ATP-depend-
ent helicase RuvB: RuvBL1 (TIP49a) and RuvBL2 (TIP49b),
which were identified in association with both MLH1 and
PMS2. RuvBL1 and RuvBL2 are highly conserved in evolution
and are essential for viability in yeast. The precise role of these
ATPase-helicases is not known, but they were reported to
be associated with transcription factors (60, 61) and to modu-
late apoptosis (62) and oncogenic transformation (63, 64), and
they were shown to be in chromatin remodeling complexes in
yeast (65, 66) as well as in a complex with the histone acetyl-
transferase TIP60 in human cells (67, 68).
We also identified several proteins with unknown function.
The presence of KIAA1018 appears to be highly significant
because of the extensive sequence coverage of this polypeptide
in the MS analysis of the complexes bound to MLH1, PMS2,
and PMS1 (see below). KIAA1018 appears to be identical to the
MTMR15 (myotubularin-related protein 15). TheMTMR pro-
teins are characterized primarily by a tyrosine phosphatase
domain and have been implicated in phosphoinositide metab-
olism, cellular growth, and differentiation. They were also
found to be mutated in human genetic diseases (69). Most
interestingly, the KIAA1018 protein was recently predicted to
contain a RAD18-like zinc finger domain and to possess an
endonuclease activity, which led to the suggestion that itmay be
involved in genome stability and maintenance (70).
Above, we described the use of TAP technology to identify
interacting partners of the MMR proteins MLH1 and PMS2.
This technique proved to be a valuable tool that allowed us to
validate known interactions and to discover new potential
binding partners of these important MutL homologues. The
biological significance of the identified interactionswill be eval-
uated for a selection of potentially interesting molecules that
will hopefully help us to better understand the MMR mecha-
nism and/or to discover novel functions of MutL in the cell.
Identification of PMS1 Interacting Partners by Co-im-
munoprecipitation—As discussed above, PMS1 is one of the pri-
mary interacting partners of MLH1, as judged from the results
of the TAP-MLH1 experiments (Table 1 and Fig. 3, A and C),
yet it appears to lack a biological function.We set out to identify
additional interacting partners of PMS1 in the hope that they
might point us to the biological function of the stable and abun-
dant heterodimer MutL. In this case, we decided against the
TAP approach for two reasons. First, no human cell lines lack-
ing PMS1 have been identified to date, which raised the possi-
bility that the tagged polypeptide might compete with the
untagged endogenous protein in the cell. Second, we do not
have a functional assay that could be used to test whether the
tag impairs the biological activity of PMS1.We therefore chose
to deploy large scale co-immunoprecipitation coupled withMS
analysis.
We immunoprecipitated PMS1 from 10 mg of HeLa whole
cell extract, using an affinity-purified anti-PMS1 antibody. The
purified preimmune serum was used as the negative control.
The PMS1 antibody efficiently precipitated PMS1 and itsmajor
partner MLH1 from whole cell extracts, whereas the preim-
mune serum failed to do so (Fig. 4A). The immunoprecipitates
were therefore separated by SDS-PAGE, the bands were visual-
ized by Coomassie Blue staining (Fig. 4B), and the sample lane
was cut into 15 slices. Following an in-gel tryptic digest, the
eluted peptides were analyzed by MS as described above. We
could identify a high number of novel PMS1-specific interact-
ing partners, a subset of which was divided into functional cat-
egories (Table 3).
The analysis identified several potentially interesting mole-
cules, but our attentionwas drawn to the presence of numerous
proteins belonging to the ubiquitylation pathway and in partic-
ular to the ubiquitin-ligase EDD1, which was detected with a
TABLE 3
Proteins co-immunoprecipitating with PMS1
The table lists a selection of proteins identified in a co-immunoprecipitate with








MLH1 3692 74 P40692
PMS1 3118 70 P54277
RFC 40 kDa 120 18 P35250
RFC 37 kDa 111 11 P35249
RFC 140 kDa 98 6 P35251
Exonuclease 1 65 10 Q5T396
RPA 40 kDa 83 12 O15160
DNAmetabolism/repair
BRCA2 224 10 P51587
MMS19-like 103 14 Q5T455
ATR 157 9 Q13535
NONO 283 28 Q9BQC5
PGK1 487 30 P00558
TOP1 403 18 P11387
MCM6 278 12 Q14566
DPOZ 229 8 O60673
SMC3 170 17 Q9UQE7
Protein import/export
Importin 3 851 24 O00410
Importin 2 312 23 P52292
Importin 9 296 11 Q96P70
RANBP9 338 20 Q96S59
RANGAP1 243 29 Q96JJ2
Ubiquitin pathway/proteasome
EDD 2558 34 O95071
UBP5 963 35 P45974
CYLD 183 7 Q9NQC7
UBP13 141 15 Q92995
Ubiquitin 111 58 P62988
RNF123 103 7 Q5XPI4
UBAP2L 101 7 Q9BTU3
PSD2 506 23 Q13200
PRS4 198 16 P62191
Herc2 213 8 O95714
Cullin 3 190 15 Q13618
Cullin 1 134 11 Q13616
USP9Y 102 6 O00507
RNF20 188 14 Q5VTR2
DNA helicases
DNA helicase B 706 23 Q8NG08
MOV10 330 14 Q9HCE1
BRIP1 159 15 Q9BX63
Cell cycle/signaling/kinases/
phospatases/apoptosis
SET binding factor 2 759 17 Q86WG5
SET binding factor 1 194 8 O95248
Cyclin T1 483 30 O60563
CDK9 444 38 P50750
PI3K-C2 443 15 O00443
CDC5-like 338 22 Q76N46
AKAP9 323 15 Q99996
PP2A regulatory subunit A- 263 22 P30153
a Derived from the Swiss-Prot data base or published data.
bMascot protein score of65 was considered significant (p 0.05).
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very high Mascot score. This suggested that PMS1 might be
post-translationally modified by ubiquitin. Our preliminary
data show that this may indeed be the case. We transiently
expressed hemagglutinin-tagged ubiquitin (HA-Ubi) in 293
cells and showed that it was expressed in high amounts (Fig. 4C,
left). Immunoprecipitation with an anti-PMS1 antibody, fol-
lowed byWestern blot with an anti-HA tag antibody, revealed a
strong signal in the HA-Ubi-transfected extracts (Fig. 4C, cen-
ter). Reblottingwith an anti-ubiquitin antibody suggested that a
substantial proportion of the latter signal was due to endoge-
nous polyubiquitylated PMS1 (Fig. 4C, right). However, the
presence in the immunoprecipitate of deubiquitylating
enzymes, such as UBP5, suggests that ubiquitylation of PMS1
may be a reversible process. Thus, it is conceivable that the
biological role of theMutL heterodimer ismodulated by ubiq-
uitylation. This could take the form of an active participation in
an as yet unidentified process of DNA metabolism. Alterna-
tively, the polyubiquitylation may merely target PMS1 for pro-
teasome-mediated degradation. We find the latter scenario
particularly attractive, since controlled degradation of PMS1
wouldmakemoreMLH1 available for heterodimerization with
its other, catalytically active interaction partners PMS2 and
MLH3. In this way, processes of DNA metabolism that rely on
the latter heterodimers could be regulated without the need for
transcriptional control.
DISCUSSION
Recent literature contains numerous examples documenting
the involvement ofMMR proteins in processes other thanmis-
match repair (1). We argued that identification of novel inter-
acting partners of the MMR proteins, and the MutL homo-
logues in particular, might provide us with important insights
into the biological roles of these proteins outside of MMR. We
opted for the TAP strategy, which has been successfully used in
the characterization of protein complexes first in S. cerevisiae
(28), but more recently also in other organisms, including
human cells. Several studies compared TAP with single-tag
purification strategies and immunoprecipitation experiments.
TAPwas shown to be significantlymore specific, yielding fewer
false positives (30). In S. cerevisiae, where large data sets are
already available, the error rate of the TAP tagmethod has been
estimated at about 15%, whereas for a single-epitope tag
method, the error rate was about 50% (71). In addition, TAP
uses mild washing conditions, allowing thus the recovery of
native complexes. When performing TAP, the expression level
of the tagged protein is an important determinant of the out-
come of the experiment. For this reason, it is preferable to avoid
the use of extracts from transiently transfected cells, where the
expression levels of the tagged proteins are often extremely
high. This may result in the identification of nonspecific inter-
actors that bind to the overexpressed or misfolded protein. It
may also make the identification of low abundant binding part-
ners more difficult. The use of stably transfected cell lines
allows for the selection of clones expressing the tagged protein
at levels comparable with wild type.
One complication of the TAP strategy is that endogenous
proteins might compete for binding partners with the stably
expressed tagged protein, reducing thus the recovery of its
interactors. To avoid this problem, it is preferable to stably
transfect a cell line that lacks the target protein. This approach
also enables testing the activity of the tagged protein in cell
extracts, providing that an appropriate assay is available. In this
study, we usedMLH1-deficient 293T cells (34) for transfection
with TAP-taggedMLH1 and PMS2-deficient HeLa12 cells (35)
for transfection with TAP-tagged
PMS2. TAP was then performed
using whole cell extracts from the
newly generated cell lines and, as
negative control, from the parental,
untransfected cells. The validity of
the approach was confirmed by the
fact that we were able to identify the
majority of the known interacting
partners of theMutL homologues in
the eluted fractions but not in the
controls. This gave us confidence
that the novel interactions we
detected are specific.
The interaction with angiomotin
is a case in point. When the binding
of MLH1 to Amot was detected, the
protein was known only as an
80-kDa polypeptide (47).We identi-
fied an interaction with a130-kDa
form, which was described only sev-
eralmonths later (48).Our data thus
showed that the specific interaction
must be mediated by the 50-kDa
N-terminal domain. Indeed, in pull-
down experiments, only the larger
FIGURE 4.Co-immunoprecipitation of PMS1-interacting partners fromHeLa cell extracts. A, Western blot
analysis of PMS1 immunoprecipitates. Only the purified anti-PMS1 antibody and not the preimmune serum
efficiently immunoprecipitated PMS1 andMLH1. B, example of large scale co-immunoprecipitation analysis of
PMS1. The experiment was performed with 5 mg of whole cell extract and 1 g of affinity-purified anti-PMS1
rabbit polyclonal antibody or purified preimmune serum. The immunoprecipitates were analyzed by SDS-
PAGE and visualized byCoomassie staining.M, molecular sizemarker (2g/band).C, 1mgofwhole cell extract
from 293 cells either mock-transfected (Mock) or transfected with a plasmid encoding HA-Ubi was incubated
with an anti-PMS1 antibody. The immunoprecipitates (IP-PMS1) and the whole cell extracts (WCE) were ana-
lyzed by Western blot using an anti-HA tag antibody (left and center) or an anti-ubiquitin antibody (right). The
smear observed on the HA-Ubi-transfected sample indicates the presence of poly-HA-ubiquitinated PMS1
(center). Incubation of the membrane with an anti-ubiquitin antibody resulted in a band at high molecular
weight that indicated endogenouspolyubiquitinated PMS1 inbothmock-transfected andHA-ubiquitin-trans-
fected cells.
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protein specifically bound toMLH1 (Fig. 3D). Although there is
little doubt that the two proteins interact, the biological signif-
icance of this interaction is not apparent. The 130-kDa isoform
of Amot localizes to the cytoplasm and associates with actin
fibers in endothelial cells; it was postulated to be involved in the
change of cell morphology during tubulogenesis (48). The role
of the 130-kDa isoform in epithelial cells is unexplored to date.
Assuming that the interaction of Amot 130 with actin fibers is
maintained also in epithelial cells, it will be of interest to test
whether cellular morphology is affected by the absence of
MLH1 or PMS2. It is also possible that the interactionmay play
a role in the nucleus; there is an emerging link between chro-
matin remodeling and polarity-determining proteins, and sev-
eral tight junction proteins have been reported to regulate tran-
scription of cell cycle-specific genes (72).
Mutations in the BRCA1 gene are linked to breast cancer
susceptibility. The protein has been implicated in the mainte-
nance of genomic instability, although its molecular mecha-
nism of action remains enigmatic. BRCA1 interacts with
BRCA1-associated RING domain 1 (73) and BRIP1 (56) as well
as with several other proteins involved in DNA metabolism,
MLH1 among them (42). Our data now show that the latter
interaction is most likelymediated via BRIP1 (Fig. 3E). It will be
important to establish whether BRIP1 plays a role in MMR as a
5–3 helicase or whether it mediates the link between MMR
and recombination. As mentioned above, MutL homologues
are implicated in both mitotic and meiotic recombination, so
finding an interacting partner implicated in recombination rep-
resents a direct confirmation of this involvement (2, 24). It is
hoped that the identification of the MutL-BRIP1-BRCA1
interaction will help shed new light on the molecular roles of
these polypeptides in the maintenance of genomic stability.
The link of the MutL homologues with recombination was
further underscored by the identification of KIAA1018. This
polypeptide of unknown function has been assigned through
sequence homology to the family of myotubularins and is ten-
tatively denominated MTMR15. However, its bacterial and
phage homologues have been shown to associate with a family
of ATP-dependent recombinases that bind DNA and facilitate
strand exchange. Moreover, BLAST homology searches identi-
fied a similarity with an archaeal Holliday junction resolvase
(70).
The analysis of the interactome of the human MutL homo-
logues MLH1, PMS1, and PMS2 identified several previously
unidentified partners of this important class of proteins. Several
of these interactions confirm the involvement of the MutL
homologues in recombination observed in genetic studies
many years ago. It could be speculated that theMutL complexes
with BRIP1 and KIAA1018, as well as with the RuvB-like pro-
teins, might function in branch migration and Holliday junc-
tion resolution.Whereas the interaction of the recombinogenic
machinery with MMRwas anticipated, the link with Amot was
totally unexpected. However, this interaction could prove to be
of substantial interest, especially if the complex can be linked to
chromatin remodeling; the mammalian MMR protein MSH6
has at its N terminus a PWWP domain (74), which has been
predicted to be involved in interactions with chromatin.
The human MMR system has recently been reconstituted
from its purified recombinant constituents (5). Our present
study provides biochemical evidence implicating the MMR
proteins, and in particular the MutL homologues, in processes
that go much beyond the repair of replication errors. We hope
that the experiments described above will open new doors,
whichwill lead to the full characterization of the biological roles
and networks involving the MMR proteins and possibly also to
a better understanding of their role in human cancer.
It is important to remember, however, that many protein-
protein interactions detected in high throughput studies such
as this may not be functionally relevant. It is possible that pro-
teins interacting in a cell extract may not interact in vivo,
because they may be confined to different cellular compart-
ments or be expressed during different stages of the cell cycle.
The biological relevance of protein-protein interactions must
therefore be substantiated by functional studies, both in vitro
and in vivo. Several of these are currently in progress in our
laboratory.
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